Global Primary Immunodeficiency Diseases Treatment Market 2017-2021

  • ID: 4416705
  • Report
  • Region: Global
  • 77 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbott
  • Baxter
  • Bristol-Myers Squibb
  • Grifols
  • Mylan
  • Sanofi
  • MORE
About Primary Immunodeficiency Diseases Treatment

Primary immunodeficiency diseases or PIDDs are disorders where part of the body's immune system is missing or not functioning properly. They weaken the body's immune system, making the patient susceptible to infections and other health problems. Treatment is palliative and includes boosting the immune system, thereby helping the patient live a normal life. The major drug classes used for the treatment and management of the disease are immunoglobulins, antibiotics, and others.

The analysts forecast the global primary immunodeficiency diseases treatment market to grow at a CAGR of 6.13% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global primary immunodeficiency diseases treatment market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Primary Immunodeficiency Diseases Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • CSL Behring
  • Grifols
  • Pfizer
  • Shire
Other prominent vendors
  • Abbott
  • ADMA Biologics
  • Astellas
  • AstraZeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb
  • BDI Pharma
  • Bharat Serums and Vaccines
  • Eli Lilly
  • GlaxoSmithKline
  • Hualan Biological Engineering
  • Kedrion Biopharma
  • LFB Group
  • Lupin Pharmaceuticals
  • Mylan
  • Novartis
  • Octapharma
  • Sanofi
  • Sanquin
  • Takeda Pharmaceutical Company
  • Valneva
  • Wockhardt
Market drivers
  • Growing number of fractionating units
  • For a full, detailed list, view the full report
Market challenges
  • High cost of treatment
  • For a full, detailed list, view the full report
Market trends
  • Shift of manufacturing facilities to low-cost regions
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Baxter
  • Bristol-Myers Squibb
  • Grifols
  • Mylan
  • Sanofi
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Market landscape
  • Market overview
  • Five forces analysis
PART 06: Pipeline landscape

PART 07: Market segmentation by therapy
  • Immunoglobulin therapy
  • Antibiotics
  • Others
PART 08: Geographical segmentation
  • PIDDs treatment market in Americas
  • PIDDs treatment market in EMEA
  • PIDDs treatment market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Shift of manufacturing facilities to low-cost regions
  • Financial aid to plasma donors
PART 12: Vendor landscape

PART 13: Key vendor analysis
  • CSL Behring
  • Grifols
  • Pfizer
  • Shire
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Features of PIDDs
Exhibit 02: Signs and symptoms of PI
Exhibit 03: PIDDs classification based on affected immune system
Exhibit 04: Diagnosis and treatment of PI
Exhibit 05: Global PIDDs treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of global PIDDs treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline analysis of vendors in global PIDDs treatment market
Exhibit 09: Key clinical trials
Exhibit 10: Market segmentation by therapy
Exhibit 11: Global PIDDs treatment market by immunoglobulin therapy 2016-2021 ($ millions)
Exhibit 12: Global PIDDs treatment market by antibiotics 2016-2021 ($ millions)
Exhibit 13: Antibiotic prophylaxis regimens in several PIDDs
Exhibit 14: Global PIDDs treatment market by others 2016-2021 ($ millions)
Exhibit 15: Segmentation of global PIDDs treatment market by geography 2016 and 2021
Exhibit 16: Global PIDDs treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Market scenario in Americas
Exhibit 18: PIDDs treatment market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: PIDDs treatment market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: PIDDs treatment market in APAC 2016-2021 ($ millions)
Exhibit 23: Fractionation capacities of key vendors
Exhibit 24: Various side effects associated with immunoglobulin therapy
Exhibit 25: Factors contributing to overall cost of production for IVIG
Exhibit 26: Detailed information regarding processes required for TGA approval
Exhibit 27: Fractionating capacities globally in 2007 and 2012
Exhibit 28: Competitive structure analysis of global PIDDs treatment market 2016
Exhibit 29: Competitive factors of global PIDDs treatment market
Exhibit 30: Market penetration of various PIDDs treatment manufacturers globally 2016
Exhibit 31: Strategic success factors of companies in global PIDDs treatment market
Exhibit 32: CSL Behring: Key highlights
Exhibit 33: CSL Behring: Strength assessment
Exhibit 34: CSL Behring: Strategy assessment
Exhibit 35: CSL Behring: Opportunity assessment
Exhibit 36: Grifols: Key highlights
Exhibit 37: Grifols: Strength assessment
Exhibit 38: Grifols: Strategy assessment
Exhibit 39: Grifols: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Shire: Key highlights
Exhibit 45: Shire: Strength assessment
Exhibit 46: Shire: Strategy assessment
Exhibit 47: Shire: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Baxter
  • Bristol-Myers Squibb
  • Grifols
  • Mylan
  • Sanofi
  • MORE
New Report Released: – Global Primary Immunodeficiency Diseases Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global primary immunodeficiency diseases treatment market: CSL Behring, Grifols, Pfizer, and Shire.

Other Prominent Vendors in the market are: Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Biocon, Bristol-Myers Squibb, BDI Pharma, Bharat Serums and Vaccines, Eli Lilly, GlaxoSmithKline, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Lupin Pharmaceuticals, Mylan, Novartis, Octapharma, Sanofi, Sanquin, Takeda Pharmaceutical Company, Valneva, and Wockhardt.

Commenting on the report, an analyst from the research team said: “One trend in the market is shift of manufacturing facilities to low-cost regions. Shift of manufacturing and fractionating centers to low-cost regions have increased in the last decade due to economic advantages. This will improve the supply of immunoglobulins in developing countries and will improve the overall distribution channel.”

According to the report, one driver in the market is growing number of fractionating units. Fractionation is a crucial step involved in the manufacture of immunoglobulins. This step involves the separation of immunoglobulins and other blood protein from plasma. The capacity of fractionating units is increasing. Data estimates suggest that in between 2013 and 2016, the capacity increased by 39.5%. This increased capacity is primarily due to the instalment of new fractionating units or expansion of existing fractionating units.

Further, the report states that one challenge in the market is high cost of treatment. The immunoglobulin therapy is the primary regimen in the treatment of PIDDs. However, the cost of treatment is high because of direct costs associated with the production of immunoglobulins. The plasma donors have to be paid. Further, high costs associated with processing, fractionating, and freeze-drying also affect the price of the final product. All these factors contribute to the overall pricing of the product, making the product expensive for the end-user.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • CSL Behring
  • Grifols
  • Pfizer
  • Shire
  • Abbott
  • ADMA Biologics
  • Astellas
  • AstraZeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb
  • BDI Pharma
  • Bharat Serums and Vaccines
  • Eli Lilly
  • GlaxoSmithKline
  • Hualan Biological Engineering
  • Kedrion Biopharma
  • LFB Group
  • Lupin Pharmaceuticals
  • Mylan
  • Novartis
  • Octapharma
  • Sanofi
  • Sanquin
  • Takeda Pharmaceutical Company
  • Valneva
  • Wockhardt
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll